IL161059A0 - Substituted benzimidazole compounds and their use for the treatment of cancer - Google Patents

Substituted benzimidazole compounds and their use for the treatment of cancer

Info

Publication number
IL161059A0
IL161059A0 IL16105902A IL16105902A IL161059A0 IL 161059 A0 IL161059 A0 IL 161059A0 IL 16105902 A IL16105902 A IL 16105902A IL 16105902 A IL16105902 A IL 16105902A IL 161059 A0 IL161059 A0 IL 161059A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
benzimidazole compounds
substituted benzimidazole
substituted
Prior art date
Application number
IL16105902A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL161059A0 publication Critical patent/IL161059A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • C07D235/32Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16105902A 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer IL161059A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (fr) 2001-09-26 2001-09-26 Benzimidazoles substitués et leur usage comme traitement du cancer
PCT/EP2002/011353 WO2003028721A2 (fr) 2001-09-26 2002-09-26 Composes de benzimidazole substitue et utilisation de ceux-ci pour le traitement du cancer

Publications (1)

Publication Number Publication Date
IL161059A0 true IL161059A0 (en) 2004-08-31

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16105902A IL161059A0 (en) 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Country Status (35)

Country Link
US (1) US7041668B2 (fr)
EP (2) EP1298125A1 (fr)
JP (1) JP4510450B2 (fr)
KR (1) KR100891439B1 (fr)
CN (1) CN100346786C (fr)
AR (1) AR037096A1 (fr)
AT (1) ATE386517T1 (fr)
AU (1) AU2002337151B2 (fr)
BR (1) BR0212856A (fr)
CA (1) CA2461622C (fr)
CO (1) CO5570675A2 (fr)
CY (1) CY1107953T1 (fr)
DE (1) DE60225159T2 (fr)
DK (1) DK1432417T3 (fr)
EA (1) EA006802B1 (fr)
ES (1) ES2301682T3 (fr)
GT (1) GT200200190A (fr)
HK (1) HK1068551A1 (fr)
HR (1) HRPK20040293B3 (fr)
HU (1) HUP0401756A3 (fr)
IL (1) IL161059A0 (fr)
ME (1) MEP16808A (fr)
MX (1) MXPA04002042A (fr)
MY (1) MY135339A (fr)
NO (1) NO327008B1 (fr)
NZ (1) NZ531246A (fr)
PA (1) PA8555501A1 (fr)
PE (1) PE20030427A1 (fr)
PL (1) PL369527A1 (fr)
PT (1) PT1432417E (fr)
RS (1) RS50896B (fr)
SI (1) SI1432417T1 (fr)
UY (1) UY27452A1 (fr)
WO (1) WO2003028721A2 (fr)
ZA (1) ZA200401887B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (fr) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Dérivés de pyridazinone comme inhibiteurs de CDK2
CA2900876A1 (fr) 2004-12-22 2006-08-17 Bhi Limited Partnership Methodes et compositions de traitement de maladies liees a l'amyloide
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
KR20160039312A (ko) * 2007-10-12 2016-04-08 애브비 바하마스 리미티드 2-((r)-2-메틸피롤리딘-2-일)-1h-벤즈이미다졸-4-카복스아미드 결정형 1
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (fr) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibiteurs d'infection par le virus de l'hépatite c
WO2017035340A1 (fr) 2015-08-25 2017-03-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'un trouble associé à un gène de proprotéine convertase subtilisine kexine (pcsk9)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
CA2461622A1 (fr) 2003-04-10
KR100891439B1 (ko) 2009-04-03
MY135339A (en) 2008-03-31
SI1432417T1 (sl) 2008-08-31
JP2005504112A (ja) 2005-02-10
CY1107953T1 (el) 2013-09-04
WO2003028721A3 (fr) 2003-12-11
HRP20040293A2 (en) 2005-06-30
NZ531246A (en) 2006-06-30
NO20041214L (no) 2004-06-24
PA8555501A1 (es) 2003-06-30
PT1432417E (pt) 2008-05-23
US7041668B2 (en) 2006-05-09
NO327008B1 (no) 2009-04-06
EP1432417A2 (fr) 2004-06-30
GT200200190A (es) 2003-11-11
JP4510450B2 (ja) 2010-07-21
AR037096A1 (es) 2004-10-20
MEP16808A (en) 2010-06-10
CN100346786C (zh) 2007-11-07
KR20040048904A (ko) 2004-06-10
BR0212856A (pt) 2004-09-14
CA2461622C (fr) 2008-12-02
ATE386517T1 (de) 2008-03-15
US20050014811A1 (en) 2005-01-20
DE60225159D1 (de) 2008-04-03
RS50896B (sr) 2010-08-31
DE60225159T2 (de) 2009-02-19
HUP0401756A2 (hu) 2005-01-28
HK1068551A1 (en) 2005-04-29
CN1558761A (zh) 2004-12-29
EA006802B1 (ru) 2006-04-28
YU21404A (sh) 2006-08-17
PL369527A1 (en) 2005-05-02
ZA200401887B (en) 2005-05-31
EA200400475A1 (ru) 2004-08-26
HRPK20040293B3 (en) 2007-06-30
HUP0401756A3 (en) 2005-06-28
AU2002337151B2 (en) 2007-04-26
EP1298125A1 (fr) 2003-04-02
MXPA04002042A (es) 2004-06-07
ES2301682T3 (es) 2008-07-01
EP1432417B1 (fr) 2008-02-20
UY27452A1 (es) 2003-02-28
CO5570675A2 (es) 2005-10-31
DK1432417T3 (da) 2008-06-16
PE20030427A1 (es) 2003-06-20
WO2003028721A2 (fr) 2003-04-10

Similar Documents

Publication Publication Date Title
HK1068551A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
EP1446012A4 (fr) Therapie bacteriolytique combinee pour le traitement de tumeurs
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HUP0500424A2 (en) Combination therapy for the treatment of cancer
AU2003212634A8 (en) Compounds useful in the treatment of cancer
EP1442062A4 (fr) Methodes de traitement du carcinome
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
PL368035A1 (en) Compositions and methods for the treatment of cancer
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1684795A4 (fr) Procedes et agents pour le traitement du cancer
PT1680405E (pt) Derivados de bengamida e sua utilização para o tratamento de doenças cancerosas
GB2415379B (en) Methyl-ß-orcinolcarboxylate from lichen (everniasrum cirrhatum) for use for the treatment of cancer
AU2002350513A1 (en) Use of solasonine for the treatment of skin tumors
GB0129388D0 (en) Use of compounds for treating cancer